Vista, CA, December 16, 2024 (GLOBE NEWSWIRE) – Mindera Health, a leading innovator in precision medicine for dermatological conditions, has announced its new partnership with MultiPlan, a national provider of healthcare network solutions. As part of the agreement, Mindera’s proprietary test, Mind.Px™, will now be accessible to health plan members using MultiPlan’s PHCS and MultiPlan Networks.
The collaboration allows psoriasis patients and their healthcare providers greater access to Mindera’s Vista, CA-based laboratory, where Mind.Px™ is conducted. The test helps physicians identify the most effective biologic treatments for patients by predicting their response to different drug classes, improving clinical outcomes and reducing unnecessary healthcare costs.
“Our goal is to drive the clinical and economic benefits of precision-guided biologic selection by ensuring broad access to our testing for psoriasis patients and their care providers,” said Ron Rocca, CEO of Mindera Health. “We are excited to partner with MultiPlan, whose networks support millions of lives and provide essential provider network solutions to employers and payers across the U.S.”
Psoriasis: A Growing Healthcare Challenge
Psoriasis, a chronic skin condition, affects over 3% of the U.S. population, equating to more than 8 million people. With annual healthcare costs exceeding $110 billion, the condition places a significant financial burden on both patients and the healthcare system. As the use of biologic drugs for psoriasis increases, spending on specialty medications continues to rise sharply. Biologics often represent a top expenditure for payers, employers, and pharmacy benefit managers.
Despite the availability of these advanced treatments, approximately 52% of psoriasis patients fail to respond to biologics, leading to extended trial-and-error treatment regimens and escalating healthcare costs. Mind.Px™ aims to reduce this inefficiency by matching patients to the most appropriate biologic treatment before therapy begins.
Mindera Health’s Innovative Approach
Mindera Health is at the forefront of a new era in skin analytics. Using a proprietary dermal biomarker patch and advanced machine learning techniques, the company offers clinically validated tests designed to improve patient outcomes and reduce healthcare system costs. The company’s CLIA- and CAP-certified laboratory is also ISO 13485:2016 certified, ensuring the highest standards of testing and patient care.
Mind.Px™: A Precision Tool for Psoriasis Treatment
Mind.Px™ is a predictive diagnostic test that utilizes a painless dermal biomarker patch to extract mRNA from the skin. The mRNA is then analyzed through transcriptomic analysis and machine learning algorithms to generate actionable insights for clinicians. With a reported positive predictive value of over 91%, Mind.Px™ helps physicians select the most effective biologic treatment for patients, improving treatment efficacy and reducing the likelihood of ineffective therapies.
A recent study indicated that the use of Mind.Px™ could save an estimated $5,138 to $13,141 per patient annually by reducing unnecessary treatments and improving outcomes. These cost savings, along with enhanced patient care, underscore the potential for precision medicine to transform the management of psoriasis.
Related topics
